Social Anxiety Disorder Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Pfizer, AstraZeneca, H. Lundbeck A/S, Vistagen Therapeutics

Posted on
by

Social Anxiety Disorder Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2023-2032), States DelveInsight | Pfizer, AstraZeneca, H. Lundbeck A/S, Vistagen Therapeutics
DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Social Anxiety Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Social Anxiety Disorder Market Forecast

 

Some of the key facts of the Social Anxiety Disorder Market Report: 

  • The Social Anxiety Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The National Institute of Mental Health (NIMH) estimates that 12.1% of people, or around 1 in 8 persons, at some point in their lives will suffer from social anxiety disorder. After depression and substance misuse, SAD is the third most prevalent psychiatric illness, according to the US National Institutes of Health (NIH). An estimated 29.9% of persons with social anxiety disorder in the last year had significant impairment
  • According to the Anxiety and Depression Association of America (ADAA) 2021, 6.8% of adults in the US, or 15 million people, suffer with social anxiety disorder. Due to the condition, many patients regularly received incorrect diagnoses
  • In the UK population, social anxiety disorder affects 12% of people over the course of their lifetimes, according to the National Institute of Health and Care Excellence (NICE)
  • According to Lisa Fritscher (2021), men are slightly more likely than women to experience Taijin kyofusho, the Japanese term for social phobia, which affects 10–20% of the general population in Japan
  • Key Social Anxiety Disorder Companies: Vistagen Therapeutics, Bionomics, EmpowerPharm, Pfizer, AstraZeneca, H. Lundbeck A/S, Cephalon, GlaxoSmithKline, Biohaven Pharmaceuticals, Bristol-Myers Squibb, UCB Pharma, Avera Pharma, Shire, and others
  • Key Social Anxiety Disorder Therapies: PH94B, BNC210, EPI-CBD-001, Pristiq, quetiapine, Escitalopram, Ziprasidone, Cabitril, paroxetine, BHV-0223, Nefazodone, levetiracetam, AV608, SPD503, and others
  • The Social Anxiety Disorder epidemiology based on gender analyzed that females are more frequently diagnosed with of social anxiety disorder compared to males
  • The Social Anxiety Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Social Anxiety Disorder pipeline products will significantly revolutionize the Social Anxiety Disorder market dynamics.

 

Social Anxiety Disorder Overview

The most prevalent mental health problem, social anxiety disorder (SAD), also known as social phobia, produces great terror in social situations and an acute, enduring fear of being seen and judged by others.

 

Get a Free sample for the Social Anxiety Disorder Market Report 

https://www.delveinsight.com/report-store/social-anxiety-disorder-market

 

Social Anxiety Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Social Anxiety Disorder Epidemiology Segmentation:

The Social Anxiety Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Social Anxiety Disorder
  • Prevalent Cases of Social Anxiety Disorder by severity
  • Gender-specific Prevalence of Social Anxiety Disorder
  • Diagnosed Cases of Episodic and Chronic Social Anxiety Disorder

 

Download the report to understand which factors are driving Social Anxiety Disorder epidemiology trends @ Social Anxiety Disorder Epidemiology Forecast

 

Social Anxiety Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Social Anxiety Disorder market or expected to get launched during the study period. The analysis covers Social Anxiety Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Social Anxiety Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Social Anxiety Disorder Therapies and Key Companies

  • PH94B: Vistagen Therapeutics
  • BNC210: Bionomics
  • EPI-CBD-001: EmpowerPharm
  • Pristiq: Pfizer
  • quetiapine: AstraZeneca
  • Escitalopram: H. Lundbeck A/S
  • Ziprasidone: Pfizer
  • Cabitril: Cephalon
  • paroxetine: GlaxoSmithKline
  • BHV-0223: Biohaven Pharmaceuticals
  • Nefazodone: Bristol-Myers Squibb
  • levetiracetam: UCB Pharma
  • AV608: Avera Pharma
  • SPD503: Shire

 

Discover more about therapies set to grab major Social Anxiety Disorder market share @ Social Anxiety Disorder Treatment Market

 

Scope of the Social Anxiety Disorder Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Social Anxiety Disorder Companies: Vistagen Therapeutics, Bionomics, EmpowerPharm, Pfizer, AstraZeneca, H. Lundbeck A/S, Cephalon, GlaxoSmithKline, Biohaven Pharmaceuticals, Bristol-Myers Squibb, UCB Pharma, Avera Pharma, Shire, and others
  • Key Social Anxiety Disorder Therapies: PH94B, BNC210, EPI-CBD-001, Pristiq, quetiapine, Escitalopram, Ziprasidone, Cabitril, paroxetine, BHV-0223, Nefazodone, levetiracetam, AV608, SPD503, and others
  • Social Anxiety Disorder Therapeutic Assessment: Social Anxiety Disorder current marketed and Social Anxiety Disorder emerging therapies
  • Social Anxiety Disorder Market Dynamics: Social Anxiety Disorder market drivers and Social Anxiety Disorder market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Social Anxiety Disorder Unmet Needs, KOL’s views, Analyst’s views, Social Anxiety Disorder Market Access and Reimbursement 

 

To know more about Social Anxiety Disorder companies working in the treatment market, visit @ Social Anxiety Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Social Anxiety Disorder Market Report Introduction

2. Executive Summary for Social Anxiety Disorder

3. SWOT analysis of Social Anxiety Disorder

4. Social Anxiety Disorder Patient Share (%) Overview at a Glance

5. Social Anxiety Disorder Market Overview at a Glance

6. Social Anxiety Disorder Disease Background and Overview

7. Social Anxiety Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Social Anxiety Disorder 

9. Social Anxiety Disorder Current Treatment and Medical Practices

10. Social Anxiety Disorder Unmet Needs

11. Social Anxiety Disorder Emerging Therapies

12. Social Anxiety Disorder Market Outlook

13. Country-Wise Social Anxiety Disorder Market Analysis (2019–2032)

14. Social Anxiety Disorder Market Access and Reimbursement of Therapies

15. Social Anxiety Disorder Market Drivers

16. Social Anxiety Disorder Market Barriers

17.  Social Anxiety Disorder Appendix

18. Social Anxiety Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/